LYEL - Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc. , a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness.
As of May 15, 2026: spot at $18.01, ATM IV 151.0%, max pain $30.00, net GEX $146.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $448.9M
- Beta
- -0.06
- 52-Week Range
- 7.65-45
- CEO
- Lynn Seely
- Employees
- 300
- IPO Date
- Jun 17, 2021
- Exchange
- NASDAQ
What LYEL Looks Like to Options Traders Today
IV rank of 30.8% sits near the 1-year median, where strategy choice depends on directional conviction and the event calendar rather than vol regime alone; positive net gamma exposure ($146) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (-0.661) prices puts richer than calls, the typical equity downside-protection skew.
What This Page Covers
The LYEL overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked LYEL overview questions
- What is LYEL?
- LYEL is the ticker symbol for Lyell Immunopharma, Inc., a listed security. Lyell Immunopharma, Inc. , a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. Listed on NASDAQ. LYEL is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the LYEL options snapshot look like today?
- As of May 15, 2026, the LYEL options snapshot shows spot at $18.01, ATM IV 151.0%, IV rank 30.8%, max pain $30.00, net GEX $146, expected move 43.29%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are LYEL's key statistics?
- Lyell Immunopharma, Inc. (LYEL) carries a market capitalization of $448.9M, beta of -0.06 relative to the broader market, 52-week range of 7.65-45. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does LYEL belong to?
- Lyell Immunopharma, Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare LYEL's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the LYEL data on this page?
- The options snapshot above is dated May 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).